This is a working overview of receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
On 7 April 2009, The Pentagon announced they spent more than $100 million in the last six months responding to and repairing damage from cyber attacks and other computer network problems. On 1 April 2009, U.S. lawmakers pushed for the appointment of a White House cyber security "czar" to dramatically escalate U.S. defenses against cyber attacks, crafting proposals that would empower the government to set and enforce security standards for private industry for the first time. On 9 February 2009, the White House announced that it will conduct a review of the country's cyber security to ensure that the Federal government of the United States cyber security initiatives are appropriately integrated, resourced and coordinated with the United States Congress and the private sector. In the wake of the 2007 cyberwar waged against Estonia, NATO established the Cooperative Cyber Defence Centre of Excellence (CCD CoE) in Tallinn, Estonia, in order to enhance the organization's cyber defence capability. The center was formally established on 14 May 2008, and it received full accreditation by NATO and attained the status of International Military Organization on 28 October 2008. Since Estonia has led international efforts to fight cybercrime, the United States Federal Bureau of Investigation says it will permanently base a computer crime expert in Estonia in 2009 to help fight international threats against computer systems.
Hemoglobin C/ beta thalassemia: common in Mediterranean and African populations generally results in a moderate form of anemia with splenomegaly. Hemoglobin D/ beta thalassemia: common in the northwestern parts of India and Pakistan (Punjab region). Hemoglobin E/ beta thalassemia: common in Cambodia, Thailand, and parts of India, it is clinically similar to β thalassemia major or β thalassemia intermedia. Hemoglobin S/ beta thalassemia: common in African and Mediterranean populations, it is clinically similar to sickle-cell anemia. Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of both the delta and beta globins. It is generally asymptomatic. There are two clinically significant combinations involving the sickle cell gene:
More recent publications have defined the usually recommended doses as 50 mg DMT and 100 mg harmaline orally. Besides DMT with harmaline, the properties and effects of oral DMT in combination with harmine have also been studied by Jonathan Ott. He found that the threshold dose was 20 or 30 mg DMT and 120 mg harmine orally. Shulgin also reported in TiHKAL that 35 to 40 mg DMT and 140 to 190 mg harmine were unmistakably active, whereas smaller doses of 30 mg DMT and 120 to 140 mg harmine orally were inactive. In notable contrast to harmaline, harmine does not have its own psychoactive effects when used at doses of up to at least 300 mg orally. In pharmahuasca, the harmala alkaloid is usually taken first and then DMT is taken 15 to 20 minutes later, although a shorter or longer interval may also be employed. The onset of oral DMT with an MAOI is within 1 hour and its duration is 4 to 6 hours.
Alexander of the United States Army Intelligence and Security Command; Hal Puthoff, of SRI International in California; remote viewer Ingo Swann and the subsequent Stargate Project, at Fort Meade in Maryland; Keith Harary, who worked with Russell Targ. Narrated by Jim Schnabel, produced by Alex Graham, directed by Bill Eagles, made by Wall to Wall Television 3 September Cybersecrecy, the mathematician Fred Piper of the Information Security Group; the UK gave out Enigma machines to Commonwealth countries for secret telecommunications, without telling these countries that the UK could read every message; Phil Zimmermann, inventor of the PGP encryption algorithm; Simon Davies (privacy advocate); when at MIT in 1976, Whitfield Diffie found how to make encryption much more secure, to have public key encryption; Mark Rotenberg; Dorothy E. Denning, and criminal methods of encryption; Wayne Madsen (journalist); Ross J. Anderson of the Department of Computer Science and Technology, University of Cambridge and how the (French-designed) A5/1 encryption for the European mobile network in the 1990s had weak security; journalist Stephen Dorril; the NSA's Clipper chip; journalist James Bamford, author of The Puzzle Palace; a documentary in the style of Panorama. Produced by David Frank, directed by Martin Durkin, made by RDF Media 10 September Guru Busters investigates the activities of people in India who claim to have mystical powers. Producer and directed by Robert Eagle, narration by Art Malik, production company Eagle & Eagle.
Sources: en.wikipedia.org
Vitamin C can be produced from glucose by two main routes. The no longer used Reichstein process, developed in the 1930s, used a single fermentation followed by a purely chemical route. The modern two-step fermentation process, originally developed in China in the 1960s, uses additional fermentation to replace part of the later chemical stages. The Reichstein process and the modern two-step fermentation processes both use glucose as the starting material, convert that to sorbitol, and then to sorbose using fermentation. The two-step fermentation process then converts sorbose to 2-keto-l-gulonic acid (KGA) through another fermentation step, avoiding an extra intermediate. Both processes yield approximately 60% vitamin C from the glucose starting point. Researchers are exploring means for one-step fermentation. China produces about 70% of the global vitamin C market. The rest is split among European Union, India and North America. The global market was expected to exceed 141 thousand metric tons in 2024. Cost per metric ton (1000 kg) in US dollars was $2,220 in Shanghai, $2,850 in Hamburg and $3,490 in the US.
In patients with hypersensitivity to opipramol or another component of the formulation Acute alcohol, sedative, analgesic, and antidepressant intoxications Acute urinary retention Acute delirium Untreated narrow-angle glaucoma Benign prostatic hyperplasia with residual urinary retention Paralytic ileus Pre-existing higher-grade atrioventricular blockages or diffuse supraventricular or ventricular stimulus conduction disturbances Combination with monoamine oxidase inhibitor (MAOI)
=== Supply shortage === In 2011, the Sanofi Pasteur plant flooded, causing problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products made with substrain Connaught such as a tuberculosis vaccine and ImmuCYST, a BCG immunotherapeutic and bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years caused shortages of bladder cancer and tuberculosis vaccines. On 29 October 2014 Health Canada gave the permission for Sanofi to resume production of BCG. A 2018 analysis of the global supply concluded that the supplies are adequate to meet forecast BCG vaccine demand, but that risks of shortages remain, mainly due to dependence of 75 percent of WHO pre-qualified supply on just two suppliers.
Traces of the drug were found on a mobile phone used by Mohamed Lahouaiej Bouhlel, a French-Tunisian who killed eighty-four civilians in Nice on Bastille Day in 2016. In May 2017, French customs at Charles de Gaulle Airport seized 750,000 fenethylline pills being transported from Lebanon to Saudi Arabia. In 2017, two other consignments of pills were found at Charles de Gaulle Airport: in January, heading for the Czech Republic, and in February, hidden in steel moulds. Further investigation showed that the seized products mainly contained a mixture of amphetamine and theophylline. In January 2018, Saudi Arabia seized 1.3 million fenethylline pills at the Al-Haditha crossing near the border with Jordan. In December 2018, Greece intercepted a Syrian ship sailing for Libya, carrying six tonnes of processed cannabis and three million fenethylline pills. In July 2019, a shipment of 33 million fenethylline pills, weighing 5.25 tonnes, was seized in Greece coming from Syria. In July 2019, 800,000 fenethylline pills were found on a boat in the United Arab Emirates. In August 2019, Saudi customs at Al-Haditha seized over 2.5 million fenethylline pills found inside a truck and a private vehicle. In February 2020, the UAE found 35 million fenethylline pills in a shipment of electric cables from Syria to Jebel Ali. In April 2020, Saudi Arabia seized 44.7 million fenethylline pills smuggled from Syria, and citing drug smuggling concerns, imposed an import ban on fruits and vegetables from Lebanon, causing the price of Lebanese lettuce to plummet.
=== Further uses and logistics integration === In the United States, drive-up banks often used pneumatic tubes to transport cash and documents between cars and tellers; by the 2020s some of these have been removed, obviated by the rise of mobile banking apps and the increasing sophistication of ATMs. Many hospitals have a computer-controlled pneumatic tube system to deliver drugs, documents, and specimens to and from laboratories and nurses' stations. Many factories use them to deliver parts quickly across large campuses. Many larger stores use systems to securely transport excess cash from checkout stands to back offices, and to send change back to cashiers. They are used in casinos to move money, chips, and cards quickly and securely. Japanese love hotels use them to allow customers to settle bills anonymously. NASA's original Mission Control Center had pneumatic tubes connecting controller consoles with staff support rooms. Mission Operations Control Room 2 was last used in its original configuration in 1992 and then remodeled for other missions. Because the room was designated a National Historic Landmark in 1985, it was decided in 2017 to restore it to its 1960s condition. The pneumatic tubes were removed and sent to the Cosmosphere in Kansas for restoration.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.